SG10201610317VA - Antibodies against cd38 for treatment of multiple myeloma - Google Patents

Antibodies against cd38 for treatment of multiple myeloma

Info

Publication number
SG10201610317VA
SG10201610317VA SG10201610317VA SG10201610317VA SG10201610317VA SG 10201610317V A SG10201610317V A SG 10201610317VA SG 10201610317V A SG10201610317V A SG 10201610317VA SG 10201610317V A SG10201610317V A SG 10201610317VA SG 10201610317V A SG10201610317V A SG 10201610317VA
Authority
SG
Singapore
Prior art keywords
treatment
antibodies against
multiple myeloma
myeloma
antibodies
Prior art date
Application number
SG10201610317VA
Other languages
English (en)
Inventor
Michel De Weers
Yvo Graus
Judith Oprins
Paul Parren Parren
Jan Van De Winkel
Martine Van Vugt
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab As filed Critical Genmab As
Publication of SG10201610317VA publication Critical patent/SG10201610317VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201610317VA 2005-03-23 2006-03-23 Antibodies against cd38 for treatment of multiple myeloma SG10201610317VA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200500429 2005-03-23
US66757905P 2005-04-01 2005-04-01
US69616305P 2005-07-01 2005-07-01
US72856105P 2005-10-20 2005-10-20

Publications (1)

Publication Number Publication Date
SG10201610317VA true SG10201610317VA (en) 2017-02-27

Family

ID=50644285

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201610317VA SG10201610317VA (en) 2005-03-23 2006-03-23 Antibodies against cd38 for treatment of multiple myeloma

Country Status (12)

Country Link
KR (1) KR20140033240A (OSRAM)
BE (1) BE2017C062I2 (OSRAM)
DK (1) DK1866338T3 (OSRAM)
ES (2) ES2606762T3 (OSRAM)
HU (2) HUE034962T2 (OSRAM)
LT (2) LT1866338T (OSRAM)
NZ (2) NZ600059A (OSRAM)
PL (1) PL1866338T3 (OSRAM)
PT (2) PT1866338T (OSRAM)
RS (1) RS55442B1 (OSRAM)
SG (1) SG10201610317VA (OSRAM)
UA (2) UA98756C2 (OSRAM)

Also Published As

Publication number Publication date
BE2017C062I2 (OSRAM) 2025-12-03
ES2606762T3 (es) 2017-03-27
LT1866338T (lt) 2017-01-25
NZ600059A (en) 2016-01-29
ES2644982T3 (es) 2017-12-01
UA98756C2 (ru) 2012-06-25
HUE030783T2 (en) 2017-06-28
HUE034962T2 (en) 2018-03-28
KR20140033240A (ko) 2014-03-17
LT2567976T (lt) 2017-12-11
PL1866338T3 (pl) 2017-04-28
DK1866338T3 (da) 2017-01-02
NZ625944A (en) 2016-01-29
RS55442B1 (sr) 2017-04-28
UA116520C2 (uk) 2018-04-10
PT2567976T (pt) 2017-10-19
PT1866338T (pt) 2016-12-14

Similar Documents

Publication Publication Date Title
IL304150A (en) Antibodies against 38cd for the treatment of multiple myeloma
HRP20181565T1 (hr) Monoklonska protutijela protiv klaudina-18 za liječenje karcinoma
PL2029155T3 (pl) Ulepszony sposób leczenia szpiczaka mnogiego
IL243687A0 (en) For the treatment of multiple myeloma 1–cs antibodies against
HK40116860A (zh) 用於治疗多发性骨髓瘤的cd38抗体
PT1962913E (pt) Radioimunoconjugado para cd66 humano para o tratamento de mieloma múltiplo
HUS1700054I1 (hu) CD38-ellenes antitestek a mielóma multiplex kezelésére
SG10201610317VA (en) Antibodies against cd38 for treatment of multiple myeloma